-- When the 2 x 750 mg Keppra XR dose was taken with food, the time to peak concentration was increased by 2 hours relative to fasted intake, while Cmax (the peak concentration of a drug in the body) remained within bioequivalence limits.
-- For all three Keppra XR dosing schedules (3 x 500 mg, 2 x 750 fasted and 2 x 750 fed), tolerability was good and the rates of treatment-emergent adverse events were similar across all groups; in addition, adverse events were virtually all mild, and all resolved by the end of the study.
Poster Session 3, Monday, December 8, 8:00 am - 1:30 pm(Abstract 3.239)
Christian Otoul, Elisabeth Rouits, Ingrid Burton, Evelyne Guenole, Mona Troenaru, Ans Valgaeren, Pierre Boulanger, Maria Laura Sargentini-Maier
UCB Pharma SA, Braine-L'Alleud, Belgium; Department of Pharmacokinetics, SGS Life Science Services, Wavre, Belgium; Therapharm Recherches, Caen, France
Additional Keppra XR Data Presented at 2008 AES Annual Meeting:
-- Population Pharmacokinetics of Levetiracetam Extended-Release 500 mg Tablets
Poster Session 3, Monday, December 8, 8:00 am - 1:30 pm(Abstract 3.247)
Elisabeth Rouits, M. Lovern, Maria Laura Sargentini-Maier and Armel Stockis
UCB Pharma, Braine-L'Alleud, Belgium
-- Population Dose-Response Modeling of Levetiracetam Extended- and Immediate-Release Formulations in Adults with Partial-Onset Seizures
Poster Session 3, Monday, December 8, 8:00 am - 1:30 pm(Abstract 3.25)
Rik Schoemaker, Eric Snoeck, Armel Stockis, Christian Otoul, Maria Laura Sargentini-Maier